LTR Pharma (ASX:LTP) Enterprise Value : A$89.44 Mil (As of Jun. 07, 2024)

View and export this data going back to 2023. Start your Free Trial

What is LTR Pharma Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, LTR Pharma's Enterprise Value is A$89.44 Mil. LTR Pharma does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Jun. 2023. Therefore, GuruFocus does not calculate LTR Pharma's EV-to-EBIT at this moment.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, LTR Pharma's Enterprise Value is A$89.44 Mil. LTR Pharma does not have enough years/quarters to calculate its EBITDA for the trailing twelve months (TTM) ended in Jun. 2023. Therefore, GuruFocus does not calculate LTR Pharma's EV-to-EBITDA at this moment.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, LTR Pharma's Enterprise Value is A$89.44 Mil. LTR Pharma does not have enough years/quarters to calculate its Revenue for the trailing twelve months (TTM) ended in Jun. 2023. Therefore, GuruFocus does not calculate LTR Pharma's EV-to-Revenue at this moment.

LTR Pharma Enterprise Value Historical Data

The historical data trend for LTR Pharma's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LTR Pharma Enterprise Value Chart

LTR Pharma Annual Data

Trend

Jun21

Jun22

Jun23

Enterprise Value

LTR Pharma Semi-Annual Data
	Jun21	Jun22	Jun23
Enterprise Value	-	-	-

Competitive Comparison of LTR Pharma's Enterprise Value

For the Biotechnology subindustry, LTR Pharma's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LTR Pharma's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LTR Pharma's Enterprise Value distribution charts can be found below:

* The bar in red indicates where LTR Pharma's Enterprise Value falls into.

LTR Pharma Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

LTR Pharma's Enterprise Value for the fiscal year that ended in Jun. 2023 is calculated as

	Enterprise Value (A: Jun. 2023 )
=	Market Cap	+	Preferred Stock	+	Long-Term Debt & Capital Lease Obligation
=	0	+	0	+	0
+	Short-Term Debt & Capital Lease Obligation	+	Minority Interest	-	Cash, Cash Equivalents, Marketable Securities
+	0	+	0	-	7.145
=	-7.15

LTR Pharma's Enterprise Value for the quarter that ended in Jun. 2023 is calculated as

	Enterprise Value (Q: Jun. 2023 )
=	Market Cap	+	Preferred Stock	+	Long-Term Debt & Capital Lease Obligation
=	0	+	0	+	0
+	Short-Term Debt & Capital Lease Obligation	+	Minority Interest	-	Cash, Cash Equivalents, Marketable Securities
+	0	+	0	-	7.145
=	-7.15

LTR Pharma (ASX:LTP) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

LTR Pharma Enterprise Value Related Terms

Thank you for viewing the detailed overview of LTR Pharma's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.

LTR Pharma (ASX:LTP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » Enterprise Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

9A/204 Alice Street, Brisbane, QLD, AUS, 4000

Website

https://www.ltrpharma.com

LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on market.

LTR Pharma (ASX:LTP) Headlines

No Headlines